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Abstract
Objective. IgG aPL against domain I of b2-glycoprotein I (b2GPI) [anti-DI (aDI)] is associated with the
pathogenesis of APS, an autoimmune disease defined by thrombosis and pregnancy morbidity. To date,
however, no study has demonstrated direct pathogenicity of IgG aDI in vivo. In this proof-of-concept
study, we designed a novel system to affinity purify polyclonal aDI aPL in order to assess its prothrom-
botic ability in a well-characterized mouse microcirculation model for APS.
Methods. Two polyclonal IgG fractions were isolated from serum of a patient with APS, both with high aPL
activity but differing in aDI activity (aDI-rich and aDI-poor). These IgG fractions were tested for their pathogenic
ability in an in vivo mouse model of thrombosis. Male CD1 mice were injected intraperitoneally with either aDI-
rich or aDI-poor IgG; as a control, IgG isolated from healthy serum was used. A pinch injury was applied to the
right femoral vein and thrombus dynamics and tissue factor activity in isolated tissue were evaluated.
Results. Both aDI-rich and aDI-poor IgG retained aCL and anti-b2GPI activity, while only aDI-rich IgG
displayed high aDI activity, as defined by our in-house cut-offs for positivity in each assay. aDI-rich IgG
induced significantly larger thrombi in vivo compared with aDI-poor IgG (P<0.0001). Similarly, aDI-rich
IgG significantly enhanced the procoagulant activity of carotid artery endothelium and peritoneal macro-
phages isolated from experimental animals (P<0.01).
Conclusion. These data directly demonstrate that the ability to cause thrombosis in vivo is concentrated
in the aDI fraction of aPL.
Key words: anti-phospholipid syndrome, anti-phospholipid antibodies, b2-glycoprotein I, domain I, venous
thrombosis, mouse model.
Introduction
APS is a systemic autoimmune disease caused by circu-
lating aPL [1]. APS is a major cause of acquired hypercoa-
gulability and recurrent pregnancy loss in the general
population [2].
Antibodies to phospholipid (PL), and to serine pro-
tease clotting factors and PL-binding proteins circulate
in the blood of patients with APS. The strongest
evidence for pathogenicity relates to antibodies against
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the PL-binding protein b2-glycoprotein I [anti-b2GPI
(ab2GPI)] [3].
b2GPI has five domains (DIDV). Although antibodies
directed against all of these domains have been reported
in patients with APS, anti-DI antibodies (aDI) are most
closely linked to pathogenicity. We [4] and other groups
[58] have shown that circulating levels of IgG aDI are
elevated in patients with APS compared with healthy
and disease controls.
We previously demonstrated that human recombinant
DI abrogated the thrombogenic ability of polyclonal
human IgG purified from a patient with APS in our well-
characterized in vivo mouse model of thrombotic APS [9],
while a human monoclonal IgG aPL, IS4, both bound DI
[10] and enhanced clot formation in the same model [11,
12]. Critically, however, no study has shown that affinity-
purified IgG aDI from patients with APS has a direct
prothrombotic effect in vivo. Therefore this study was de-
signed to test the hypothesis that the ability to cause
thrombosis in mice is concentrated in the aDI fraction of
polyclonal IgG derived from serum of a patient with APS.
Patients and methods
Affinity purification of anti-DI antibodies
Serum was obtained from a female patient with APS.
Polyclonal IgG from this patient has previously been
shown to cause thrombosis in our mouse model [13].
Patient serum was fractionated into aDI-rich and aDI-
poor fractions as follows: human recombinant hexahisti-
dine-tagged DI was produced and purified as described
previously [10, 14]. Immobilized-nickel resin beads
(Promega, Madison, WI, USA) were equilibrated with
PBS (pH 7.4), followed by incubation with purified DI
(50 mg DI/100ml resin) for 30 min. DI-coupled beads were
incubated with patient serum (1 ml serum/100ml resin) for
1 h. The beads were then spun, the flow-through was col-
lected (aDI-poor fraction) and beads were washed with
PBS. Captured aDI antibodies (aDI-rich fraction) were
eluted from the beads with 0.1 M glycine (pH 2.7), con-
centrated and dialysed in PBS (Amicon Pro centrifugal
devices, Millipore, Billerica, MA, USA).
Human polyclonal IgG purification
IgG was purified from both aDI-rich and aDI-poor fractions
using protein G chromatography (ThermoScientific Pierce,
Rockford, IL, USA). Pooled sera from 10 healthy donors
who tested negative for aPL [normal human serum (NHS)]
were used as a source of control IgG. aDI-rich IgG, aDI-
poor IgG and NHS-IgG were concentrated and dialysed in
PBS and were confirmed to be free of endotoxin by the
limulus amoebocyte lysate assay (Sigma, St Louis, MO
USA). All research subjects who donated serum signed
informed consent according to the Declaration of
Helsinki and the study was approved by the Institutional
Review Board of the University of Texas Medical Branch.
Immunological characterization of serum and purified
polyclonal IgG
IgG aCL, ab2GPI and aDI activity were measured in human
serum (diluted 1:50), purified human IgG (aDI-rich, aDI-
poor and IgG purified from unfractionated serum, all
tested at 100mg/ml) and mouse serum (diluted 1:10)
using direct ELISA as described previously [4]. Total
human IgG circulating in mouse serum was measured
by ELISA [12].
To determine the avidity of purified IgG to CL, b2GPI or
DI, we tested IgG (at 100mg/ml) in the presence of
increasing salt concentrations (range 0.154 M NaCl,
where PBS has 0.15 M NaCl).
aCL activity was defined as IgG phospholipid units
(GPLU), using commercially sourced calibrators
(Louisville aPL Diagnostics, Seabrook, TX, USA; activity
range <16 to >96 GPLU), while ab2GPI and aDI activity
were defined as IgG b2GPI units (GBU) and DI units
(GDIU), respectively, using in-house calibrators (activity
range <3.1 to >100 for both tests). Based on sera from
a population of 200 healthy subjects, our cut-offs for aPL
positivity in these assays are (defined as the mean + 3 S.D.
of the activity of healthy subjects) 17 GPLU, 8 GBU, and
10 GDIU.
In vivo induction of thrombosis and analysis of
thrombus dynamics
Five to 10 male CD1 mice (Charles River Laboratories,
Cambridge, MA, USA) per group were injected intraperi-
toneally twice (at time 0 and 48 h later) with either 100 mg
of aDI-rich or aDI-poor IgG (n= 10/group) or NHS-IgG
(n= 5). Mice were anaesthetized 72 h after the first injec-
tion. The right femoral vein was exposed and pinched
using a standard pressure to induce injury. Thrombus dy-
namics were assessed as described previously [9, 15, 16].
Serum was obtained for ELISA after the surgical
procedure.
Tissue factor activity in carotid homogenates and
peritoneal macrophages
At the end of the surgical procedures, uninjured carotids
were placed into Tris-buffered saline0.01% Triton X-100
buffer containing heparin. Peritoneal macrophages were
collected by flushing the peritoneal cavity with PBS for
5 min. After sonication, tissue factor (TF) activity was
determined using a commercial chromogenic assay
(Human Tissue Factor Activity Kit, AssayPro, St Charles,
MO, USA). TF activity data were normalized using the pro-
tein concentration as reference and expressed as pM/mg/
ml protein [16].
Statistical analysis
Differences between groups were analysed by the follow-
ing methods: thrombus size, one-way analysis of variance
(ANOVA) followed by Tukey’s multiple comparison test; TF
activity, non-parametric unpaired t-tests with Welch’s
correction; human aPL activity in mouse serum, Mann-
Whitney test; and total human IgG in mouse serum, one-
way ANOVA followed by Dunn’s multiple comparison
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tests. P-values< 0.05 denote a statistical difference be-
tween groups. Analysis was carried out with GraphPad
Prism version 5.0 (GraphPad Software, La Jolla, CA, USA).
Results
Binding properties of aDI-rich and aDI-poor fractions
aCL, ab2GPI and aDI titres for APS serum were
>96 GPLU, 93.9 GBU and 50.2 GDIU, respectively. As illu-
strated in Fig. 1, purified IgG (100 mg/ml) from unfractio-
nated serum was highly positive in all three assays, with
values >96 GPLU, >100 GBU and 89.4 GDIU. aDI-rich IgG
maintained high activity against all three antigens
(>96 GPLU, >100 GBU, >100 GDIU); as expected, aDI
activity was enriched compared with unfractionated IgG.
Conversely, aDI-poor IgG confirmed reduced binding to
these antigens (89.3 GPLU, 46.8 GBU, 17 GDIU); the
reduction in aDI activity was by far the greatest
(Fig. 1AC). Both aDI-rich and aDI-poor IgG retained
aCL, ab2GPI and aDI activity above the cut-off values for
positivity in each assay. All samples from healthy controls
were negative in all three assays.
We determined the avidity of both aDI-rich and aDI-
poor fractions for CL, b2GPI and DI, comparing results
with unfractionated IgG (Fig. 1DF). In all three assays
the activity of aDI-poor IgG was reduced by 50%
when NaCl was marginally increased from 0.15 to
0.25 M. In contrast, aDI-rich IgG retained >90% ab2GPI
and aDI activity even at 4.0 M NaCl; aCL activity was
reduced, but only at 52.0 M NaCl. Thus, although the
aDI-poor fraction retained high aCL and ab2GPI activity,
these aPLs were of low avidity compared with the high
avidity aPL in the aDI-rich fraction.
Mice injected with aDI-rich IgG had significantly higher
aPL titres in all three assays compared with mice that
received aDI-poor IgG (mean activity of the aDI-rich
group: 39.5 GPLU, 40.1 GBU, 16.6 GDIU; aDI-poor
group: 9.3 GPLU, 13.3 GBU, 4.7 GDIU) (n= 9 mice/group,
P< 0.001 in all cases). Circulating human IgG was con-
firmed to be present in all mice. Human IgG levels did not
differ significantly between mice injected with aDI-rich and
aDI-poor IgG samples (data not shown).
In vivo thrombus-generation results
aDI-rich IgG induced significantly larger thrombi in vivo
[mean thrombus size 1848.1 mm2 (S.D. 729.2) compared
with aDI-poor [960.5mm2 (S.D. 258.6)] or NHS-IgG
[525.1 mm2 (S.D. 136.2)] (P< 0.0001 in both cases)
(Fig. 2A). The aDI-poor fraction retained some prothrom-
botic potential, as the thrombi in these mice were signifi-
cantly larger compared with mice treated with NHS-IgG
(P< 0.0001).
Ex vivo tissue factor activity
Both APS-derived IgG preparations increased carotid TF
activity compared with NHS-IgG [mean TF activity
149.0 pM/mg/ml (S.D. 21.1)], by a factor of 2.4-fold for
aDI-rich IgG [402.5 (S.D. 165.2)] and by 1.4-fold for aDI-
poor IgG [223.1 (S.D. 71.8)]. However, treatment with
aDI-rich IgG resulted in significantly enhanced carotid TF
FIG. 1 Binding properties of purified IgG fractions to cardiolipin, b2GPI and DI
Purified IgG from unfractionated serum, aDI-rich and aDI-poor IgG from fractionated serum were tested at 100 mg/ml for
(A) aCL, (B) ab2GPI and (C) aDI activity in a dose-dependent manner. Results are expressed in IgG phospholipid units
(GPLU), b2GPI units (GBU) and DI units (GDIU), respectively. The avidity of purified IgG (D) to CL, (E) b2GPI and (F) DI was
determined by incubating IgG (at 100mg/ml) with increasing NaCl concentrations (0.15 M original concentration in PBS,
0.25 M, 0.5 M, 1 M, 2 M and 4 M). Results are shown as a percentage of aPL activity retained, where 100% represents
activity at 0.15 M NaCl. b2GPI: b2-glycoprotein I; DI: domain I; aDI: anti-DI; ab2GPI: anti-b2GPI.
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activity compared with aDI-poor IgG (1.6-fold difference,
P= 0.005; Fig. 2B).
In peritoneal macrophages, treatment with aDI-rich IgG
greatly enhanced TF activity by a factor of 3.5-fold com-
pared with aDI-poor IgG [106.9 (S.D. 55.5) vs 28.5 (S.D.
14.1), respectively; P= 0.003]. aDI-poor IgG did not pro-
duce any increase in macrophage TF activity compared
with NHS-IgG [30.6 (S.D. 4.1); Fig. 2C].
Discussion
Previously we showed that recombinant human DI could
inhibit the ability of polyclonal human IgG from a patient
with APS to cause thrombosis or to enhance TF activity in
the same in vivo mouse model that is described here [9]. In
this report we used polyclonal IgG from a different patient
with APS. In all three outcome measures, aDI-rich IgG
significantly enhanced prothrombotic ability in vivo com-
pared with aDI-poor or NHS-IgG. These findings are con-
sistent with our hypothesis that the ability of human
APS-derived IgG to cause thrombosis in mice is concen-
trated in the aDI-rich fraction. Notably the aDI-poor frac-
tion retained some prothrombotic capacity, which may be
due to (some) residual aDI activity, retained ab2GPI activ-
ity (presumably binding to epitopes in DIIV) or caused
by other prothrombotic IgG antibodies such as anti-
prothrombin (PT) or anti-PT/phosphatidylserine [17].
Limitations of this work are that a single patient’s
sample was used and that we were unable to compare
the effects of aDI-rich IgG with IgG affinity-purified for
binding to another region of b2GPI. Our expression
system is currently designed to produce DI only, however,
in the future it may be possible to carry out a similar ex-
periment to test IgG specific for different domains. Our
hypothesis predicts that enrichment of IgG specific to
other b2GPI domains would not enhance the ability to
cause thrombosis—all such non-aDI antibodies should
be present in the aDI-poor sample used in this study.
The identification of DI as the key antigenic region for
pathogenic IgG aPL [4, 5, 7] paved the way for studies
reporting the association of circulating aDI with APS [8]
and the ability of recombinant DI to inhibit aPL-induced
thrombosis in vivo [9]. Importantly, a synthetic monoclonal
IgG aDI (MMB2) was very recently been shown to cause
complement-mediated thrombosis and fetal loss in vivo
[18], while IgG recognizing a peptide derived from the
human DI sequence induced monocyte and endothelial
cell activation and bound Toll-like receptor 4 (TLR4)
in vitro. In fact, the DI-derived peptide shared sequence
homology with an epitope on TLR4 [19]. Both complement
FIG. 2 Assessing in vivo thrombus generation and ex vivo TF activity
(A) Significantly larger thrombi were generated in the presence of aDI-rich IgG compared with either aDI-poor IgG or
NHS-IgG. Significantly larger thrombi were also noted with aDI-poor IgG compared with NHS-IgG. Results are shown as
mean thrombus size (mm2) with S.D. error bars. ***P< 0.0001. Significantly greater TF activity was seen in (B) carotid artery
endothelial cells and (C) peritoneal macrophages isolated from mice treated with aDI-rich IgG compared with both aDI-
poor IgG and NHS-IgG. Results are shown as the mean TF activity (pM/mg/ml) with S.D. error bars. **P< 0.01. TF: tissue
factor; aDI: anti-domain I; NHS: normal human serum.
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and TLR4 are historically implicated in aPL-stimulated
pathogenesis and these two studies are the first to sug-
gest that specifically aDI can drive cell damage via TLR4
and/or complement activation.
Designing a test for the detection of aDI [17] could have
both diagnostic and prognostic value, allowing us to
assess the susceptibility of a patient to develop an APS-
related clinical manifestation. In addition, creating thera-
peutic agents that target aDI could offer a novel approach
for treating APS [20]. Our results have provided direct evi-
dence that human aDI is prothrombotic in vivo, thus
emphasizing the importance of measuring circulating aDI
for APS diagnosis and further highlighting the thera-
peutic potential of recombinant DI as a decoy for patho-
genic aPL.
Rheumatology key messages
. First direct evidence that aDI IgG from APS patients
is prothrombotic in vivo.
. aDI-poor IgG partially retained in vivo prothrombotic
ability.
. aDI-rich IgG significantly enhanced endothelial and
macrophage tissue factor activity compared with
aDI-poor IgG.
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